The NUDIX hydrolase NUDT5 regulates thiopurine metabolism and cytotoxicity
Journal of Clinical Investigation · 15.07.2025 · 135 (14)
DOI: 10.1172/jci190443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.07.2025. Verfasst von Maud Maillard und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences and. Hauptthemen laut MEDLINE: Pyrophosphatases, Mercaptopurine, Neoplasm Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Thiopurines are anticancer agents used for the treatment of leukemia and autoimmune diseases. These purine analogs are characterized by a narrow therapeutic index because of the risk of myelosuppression. With the discovery of NUDIX hydrolase 15 (NUDT15) as a major modulator of thiopurine metabolism and toxicity, we sought to comprehensively examine all members of the NUDIX hydrolase family for their effect on the pharmacologic effects of thiopurine. By performing a NUDIX -targeted CRISPR/Cas9 screen in leukemia cells, we identified NUDT5 , whose depletion led to drastic thiopurine resistance. NUDT5 deficiency resulted in a nearly complete depletion of active metabolites of thiopurine and the loss of thioguanine incorporation into DNA. Mechanistically, NUDT5 deletion resulted in substantial alteration in purine nucleotide biosynthesis, as determined by steady-state metabolomics profiling. Stable isotope tracing demonstrated that the loss of NUDT5 was linked to a marked suppression of the purine salvage pathway but with minimal effects on purine de novo synthesis. Finally, we comprehensively identified germline genetic variants in NUDT5 associated with thiopurine-induced myelosuppression in 582 children with acute lymphoblastic leukemia. Collectively, these results pointed to NUDT5 as a key regulator of the thiopurine response primarily through its effects on purine homeostasis, highlighting its potential to inform individualized thiopurine therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy and Pharmaceutical Sciences and.
- Department of Pathology, Center of Excellence for Leukemia Studies, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
- Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
- Institute for Cancer Outcomes and Survivorship and Division of Pediatric Hematology-Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Departments of Clinical Pharmacology, and of Biochemistry and Pharmacy and.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
- American Lebanese Syrian Associated Charities
Zitieren
APA
Maillard, M., Nishii, R., Vu, H. S., Bhattarai, K. R., Yang, W., Li, J., Hofmann, U., Savic, D., Bhatia, S., Schwab, M., Ni, M., & Yang, J. J. (2025). The NUDIX hydrolase NUDT5 regulates thiopurine metabolism and cytotoxicity. Journal of Clinical Investigation, 135(14). https://doi.org/10.1172/jci190443
Vancouver
Maillard M, Nishii R, Vu HS, Bhattarai KR, Yang W, Li J, et al. The NUDIX hydrolase NUDT5 regulates thiopurine metabolism and cytotoxicity. Journal of Clinical Investigation. 2025;135(14). doi:10.1172/jci190443
BibTeX
@article{Maillard2025,
author = {Maillard, Maud and Nishii, Rina and Vu, Hieu S and Bhattarai, Kashi R and Yang, Wenjian and Li, Jing and Hofmann, Ute and Savic, Daniel and Bhatia, Smita and Schwab, Matthias and Ni, Min and Yang, Jun J},
title = {The NUDIX hydrolase NUDT5 regulates thiopurine metabolism and cytotoxicity},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {14},
doi = {10.1172/jci190443}
}
EUVIMED